BAM15

A research uncoupler — same mechanism family as DNP (making mitochondria waste calories as heat) — promoted on mouse studies showing fat loss without DNP's hyperthermia signature.

BAM15 is a mitochondrial uncoupler — the same broad mechanism as DNP, which is the first thing anyone considering it should know. It dissipates the proton gradient mitochondria use to make ATP, so energy is released as heat and fat is burned at an increased rate. The claimed advance over DNP is selectivity: BAM15 was designed to act on mitochondrial membranes without depolarising the plasma membrane, which in animal work produced fat loss without the lethal hyperthermia that makes DNP so dangerous. That is a real and interesting design goal. It has not been demonstrated in a human being.

Mouse and cell data only. "Safer than DNP in mice" is the entire safety claim, and DNP set the bar at "kills people," so clearing it means little. No human has been studied.

• NONE. There is no human trial of BAM15 of any size or phase.
• The animal work is genuinely more encouraging than DNP's — mice lost fat without the temperature rise and without the narrow margin that kills people on DNP.
• That improved animal safety margin is exactly what cannot be assumed to transfer. DNP's lethality in humans is a matter of dose accumulation and individual variation under real conditions, and no one has tested whether BAM15's margin holds outside a controlled animal facility.
• Uncoupling is a mechanism with an unusually unforgiving history in humans: DNP killed people in the 1930s and continues to kill people now. A compound in that class with no human data deserves that history as context rather than a footnote.
• Sold as research-chemical supply of unverified identity, which for a compound in this class is a compounding risk rather than an incidental one.

Human pharmacokinetics have never been characterised. No half-life, bioavailability or clearance figure exists for people — which matters more here than for most compounds, because what makes DNP lethal is accumulation across days from a long half-life. Whether BAM15 accumulates similarly in humans is unknown.

Uncoupling is the highest-stakes mechanism in metabolism — DNP's fatality record (see that entry) is mechanism-driven, and BAM15 shares the mechanism with a dose-response curve mapped only in rodents. Human margin of safety: unknown. This entry exists because the name circulates, not because the mouse data transfers.

• Everyone — a mitochondrial uncoupler with zero human data, in a class with a documented history of deaths
• Anyone treating the animal safety data as if it were human safety data
• Anyone pregnant or breastfeeding

• No characterised human interaction profile exists.
• Heat, stimulants, thyroid hormone and dehydration are the mechanistic concerns for any uncoupler, based on what is known from DNP rather than from any BAM15 data.

• There is no established monitoring, and constructing a temperature-watching protocol would be actively dangerous — it would import a false sense of control from the DNP discussion into a compound nobody has studied.
• The relevant fact: any uncoupler that raises body temperature can do so faster than a person can respond. If someone taking any uncoupling agent is overheating, that is an emergency call immediately, naming the compound.

Nothing is established about stopping, because nothing is established about taking it. For uncouplers generally the concern is that exposure persists after the last dose and effects can continue building — that is documented for DNP and unknown for this compound. Anyone who has taken any uncoupling agent and develops fever, heavy sweating, a racing heart or agitation needs emergency care immediately and must say what they took.

US: not FDA-approved for human use; unscheduled.

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

• Targeting Mitochondrial Dysfunction to Prevent Endothelial Dysfunction and Atherosclerosis in Diabetes: Focus on the Novel Uncoupler BAM15
  Int J Mol Sci, 2025
• BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases
  Front Endocrinol (Lausanne), 2023

• BAM15 treats mouse sepsis and kidney injury, linking mortality, mitochondrial DNA, tubule damage, and neutrophilsJ Clin Invest · 2023
• BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseasesFront Endocrinol (Lausanne) · 2023
• BAM15 inhibits endothelial pyroptosis via the NLRP3/ASC/caspase-1 pathway to alleviate atherosclerosisAtherosclerosis · 2025
• Beneficial effects of MGL-3196 and BAM15 combination in a mouse model of fatty liver diseaseActa Physiol (Oxf) · 2024
• BAM15 Relieves Neurodegeneration in Aged Caenorhabditis elegans and Extends LifespanMetabolites · 2022
• BAM15 attenuates transportation-induced apoptosis in iPS-differentiated retinal tissueStem Cell Res Ther · 2019
• BAM15-mediated mitochondrial uncoupling protects against obesity and improves glycemic controlEMBO Mol Med · 2020
• The new mitochondrial uncoupler BAM15 induces ROS production for treatment of acute myeloid leukemiaBiochem Pharmacol · 2022
• BAM15 improves oocyte quality against obesity via PPARγ-dependent mitochondrial functionProtein Cell · 2026
• Mitochondrial uncoupling attenuates sarcopenic obesity by enhancing skeletal muscle mitophagy and quality controlJ Cachexia Sarcopenia Muscle · 2022
• Targeting Mitochondrial Dysfunction to Prevent Endothelial Dysfunction and Atherosclerosis in Diabetes: Focus on the Novel Uncoupler BAM15Int J Mol Sci · 2025
• BAM15, a Mitochondrial Uncoupling Agent, Attenuates Inflammation in the LPS Injection Mouse Model: An Adjunctive Anti-Inflammation on Macrophages and HepatocytesJ Innate Immun · 2021